<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676336</url>
  </required_header>
  <id_info>
    <org_study_id>16VBHB</org_study_id>
    <nct_id>NCT02676336</nct_id>
  </id_info>
  <brief_title>A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioPharmX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioPharmX, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo controlled, multi-center study to evaluate the&#xD;
      safety, tolerability and potential effects of dietary supplement Violet™ Iodine on breast&#xD;
      health in women with cyclic breast discomfort and tenderness to eliminate the evaluation of&#xD;
      effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in self assessed cyclic breast discomfort</measure>
    <time_frame>After 6 months of active treatment with molecular iodine (I2) compared to placebo</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Fibrocystic Breast Condition (FBC)</condition>
  <arm_group>
    <arm_group_label>Violet™ Iodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3mg molecular iodine (I2) daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3mg placebo daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-over</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on placebo will be offered 3 months of active post-treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Violet™ Molecular Iodine (I2)</intervention_name>
    <arm_group_label>Cross-over</arm_group_label>
    <arm_group_label>Violet™ Iodine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy premenopausal females ≥ 18 years of age&#xD;
&#xD;
          -  BMI 20.0 - 29.9 kg/m2 (± 1 kg/m2)&#xD;
&#xD;
          -  Females of childbearing potential must agree to use a reliable and consistent method&#xD;
             of birth control in the Investigator's opinion, excluding depot contraceptives and&#xD;
             Explanon, and have a negative urine pregnancy test result. Hormonal contraceptives&#xD;
             such as oral contraceptives, birth control patch (Ortho Evra), vaginal contraceptive&#xD;
             ring (NuvaRing) are all acceptable as long as the subject is on a stable dose and&#xD;
             agrees not to change during the study period&#xD;
&#xD;
          -  No apparent health conditions that in the investigator's opinion would interfere with&#xD;
             study participation, compliance or interpretation of endpoints or would not be in the&#xD;
             best interest of the subject&#xD;
&#xD;
          -  Moderate to severe cyclic breast discomfort of at least 4 days per month (discomfort&#xD;
             ≥4 on a 0-10 scale)&#xD;
&#xD;
          -  No known medical or psychological condition that in the investigator's opinion could&#xD;
             interfere with study participation&#xD;
&#xD;
          -  Agrees to comply with all study related procedures and visits including access to a&#xD;
             smartphone (Android or iOS) and ability to enter daily diary information via a smart&#xD;
             phone app&#xD;
&#xD;
          -  Capable of reading and understanding study related materials (in English or French)&#xD;
             and has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breast feeding, or planning to become pregnant during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Perimenopausal or irregular menstrual cycles&#xD;
&#xD;
          -  Women who have had an oophorectomy&#xD;
&#xD;
          -  Known thyroid condition or currently taking any thyroid medications&#xD;
&#xD;
          -  Prior bariatric surgery or other interventions or medications that might affect&#xD;
             gastric pH&#xD;
&#xD;
          -  Use of iodine supplementation, Tamoxifen, Lupron, or Danazol, in the last 6 months&#xD;
&#xD;
          -  Clinically significant abnormal laboratory results at Screening&#xD;
&#xD;
          -  Breast implant surgeries that have not fully healed or have ongoing problems&#xD;
             associated with the implant (i.e. seroma, infection etc.)&#xD;
&#xD;
          -  Planned elective surgeries to occur during participation in the study&#xD;
&#xD;
          -  Known allergy or sensitivity to study product ingredients (e.g. Iodine)&#xD;
&#xD;
          -  History of alcohol or drug abuse within the past year&#xD;
&#xD;
          -  Use of medicinal marijuana within the past year&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to randomization or&#xD;
             plans to participate in any other study during the next 11 months&#xD;
&#xD;
          -  Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures, may confound interpretation&#xD;
             of study outcome measures (such as another condition) or which may pose significant&#xD;
             risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KGK Synergize</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Synergize</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FBC</keyword>
  <keyword>cyclic mastalgia</keyword>
  <keyword>breast discomfort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrocystic Breast Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

